EN / 中文
您的位置： 首页 > 2024年1月 第55卷 第1期 > 文字全文
2023年7月 第38卷 第7期11
目录

结直肠癌的早期诊断策略和治疗进展

Early diagnostic strategies and therapeutic advances in colorectal cancer

来源期刊： 广州医药 | 1-8 发布时间：2024-01-24 收稿时间：2025/11/13 18:51:22 阅读量：150
作者：
黄庆,
索彩霞,
何凤,
罗青青,
李旺林,
曹杰,
关键词：
结直肠癌筛查早期诊断手术治疗靶向治疗
colorectal cancerscreeningearly diagnosissurgical treatmenttargeted therapy
DOI：
10.3969/j.issn.1000-8535.2024.01.001
收稿时间：
2023-11-14 
修订日期：
 
接收日期：
 
引用总数：
30  
通过筛查和早期发现,可以降低结直肠癌（CRC）的发病率,有效切除肿瘤病变可以降低CRC的病死率。虽然对CRC的危险因素、发病机制和前体病变的了解已经取得进展,但最近年轻人群CRC发病率升高,原因尚不清楚。在过去十年中,出现了多种侵入性、半侵入性和非侵入性筛查方式。目前对结肠镜检查质量的重视提高了筛查的有效性,人工智能等影像新技术在肿瘤检测中的作用正在迅速显现。而且,CRC有效干预措施,如保肛治疗新术式、靶向治疗及免疫治疗领域的新进展,被证明可以提高CRC患者的生存率。该文旨在总结目前国内外CRC筛查方式和指南的证据,并综述CRC治疗领域的进展。
The incidence of colorectal cancer（CRC）can be reduced through screening and early detection．Effective resection of tumor lesions reduces mortality from CRC．Although progress has been made in understanding the risk factors,pathogenesis and precursor lesions of CRC,the reasons for the recent increase in the incidence of CRC in young adults are largely unknown．A variety of invasive,semi-invasive and non-invasive screening modalities have emerged in the last decade．The current emphasis on the quality of colonoscopy has improved the effectiveness of screening,and the role of new imaging technologies such as artificial intelligence in tumor detection is rapidly emerging．Moreover,there are effective interventions for CRC,such as new surgical modalities for anal preservation therapy,and new advances in the field of targeted therapy and immunotherapy,which have been shown to improve the survival rate of CRC．The aim of this article is to summarize the current evidence on CRC screening modalities and guidelines both nationally and internationally,and to provide an overview of advances in the field of CRC treatment．
1、 YANG Z,WU G,ZHANG X,et al.Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer[J].Front Immunol,2022(13):1001444. YANG Z,WU G,ZHANG X,et al.Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer[J].Front Immunol,2022(13):1001444.
2、 WEN L,TONG F,ZHANG R,et al.The research progress of PD-1/PD-L1 inhibitors enhancing radiotherapy efficacy[J].Front Oncol,2021(11):799957. WEN L,TONG F,ZHANG R,et al.The research progress of PD-1/PD-L1 inhibitors enhancing radiotherapy efficacy[J].Front Oncol,2021(11):799957.
3、 WANG Y J,FLETCHER R,YU J,et al.Immunogenic effects of chemotherapy-induced tumor cell death[J].Genes Dis,2018,5(3):194-203. WANG Y J,FLETCHER R,YU J,et al.Immunogenic effects of chemotherapy-induced tumor cell death[J].Genes Dis,2018,5(3):194-203.
4、 CHEN G,JIN Y,GUAN W L,et al.Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient,locally advanced rectal cancer:An open-label,single-centre phase 2 study[J].Lancet Gastroenterol Hepatol,2023,8(5):422-431. CHEN G,JIN Y,GUAN W L,et al.Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient,locally advanced rectal cancer:An open-label,single-centre phase 2 study[J].Lancet Gastroenterol Hepatol,2023,8(5):422-431.
5、 WANG Q X,XIAO B Y,CHENG Y,et al.Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer:A multicentre cohort study[J].Eur J Cancer,2022(174):176-184. WANG Q X,XIAO B Y,CHENG Y,et al.Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer:A multicentre cohort study[J].Eur J Cancer,2022(174):176-184.
6、 CERCEK A,LUMISH M,SINOPOLI J,et al.PD-1 blockade in mismatch repair-deficient,locally advanced rectal cancer[J].New Engl J Med,2022,386(25):2363-2376. CERCEK A,LUMISH M,SINOPOLI J,et al.PD-1 blockade in mismatch repair-deficient,locally advanced rectal cancer[J].New Engl J Med,2022,386(25):2363-2376.
7、 CERCEK A,LUMISH M A,SINOPOLI J C,et al.Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer[J].J Clin Oncol,2022,40(17_suppl):LBA5. CERCEK A,LUMISH M A,SINOPOLI J C,et al.Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer[J].J Clin Oncol,2022,40(17_suppl):LBA5.
8、 LIPSON E J,SHARFMAN W H,DRAKE C G,et al.Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody[J].Clin Cancer Res,2013,19(2):462-468. LIPSON E J,SHARFMAN W H,DRAKE C G,et al.Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody[J].Clin Cancer Res,2013,19(2):462-468.
9、 YAEGER R,WEISS J,PELSTER M S,et al.Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C[J].N Engl J Med,2023,388(1):44-54. YAEGER R,WEISS J,PELSTER M S,et al.Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C[J].N Engl J Med,2023,388(1):44-54.
10、 DASARI A,LONARDI S,GARCIA-CARBONERO R,et al.Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer(FRESCO-2):An international,multicentre,randomised,double-blind,phase 3 study[J].Lancet,2023,402(10395):41-53. DASARI A,LONARDI S,GARCIA-CARBONERO R,et al.Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer(FRESCO-2):An international,multicentre,randomised,double-blind,phase 3 study[J].Lancet,2023,402(10395):41-53.
11、 顾艳宏,姜争,李健,等.结直肠癌靶向治疗中国专家共识[J].中华普通外科学文献(电子版),2023,17(1):1-8. 顾艳宏,姜争,李健,等.结直肠癌靶向治疗中国专家共识[J].中华普通外科学文献(电子版),2023,17(1):1-8.
12、 PRAGER G W,TAIEB J,FAKIH M,et al.Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer[J].N Engl J Med,2023,388(18):1657-1667. PRAGER G W,TAIEB J,FAKIH M,et al.Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer[J].N Engl J Med,2023,388(18):1657-1667.
13、 SCHRAG D,SHI Q,WEISER M R,et al.Preoperative treatment of locally advanced rectal cancer[J].N Engl J Med,2023,389(4):322-334. SCHRAG D,SHI Q,WEISER M R,et al.Preoperative treatment of locally advanced rectal cancer[J].N Engl J Med,2023,389(4):322-334.
14、 DENG Y,CHI P,LAN P,et al.Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer:Final results of the Chinese FOWARC trial[J].J Clin Oncol,2019,37(34):3223-3233. DENG Y,CHI P,LAN P,et al.Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer:Final results of the Chinese FOWARC trial[J].J Clin Oncol,2019,37(34):3223-3233.
15、 YANG W F,CHEN W,HE Z,et al.Simple transanal total mesorectal resection versus laparoscopic transabdominal total mesorectal resection for the treatment of low rectal cancer:A single-center retrospective case-control study[J].Front Surg,2023(10):1171382. YANG W F,CHEN W,HE Z,et al.Simple transanal total mesorectal resection versus laparoscopic transabdominal total mesorectal resection for the treatment of low rectal cancer:A single-center retrospective case-control study[J].Front Surg,2023(10):1171382.
16、 LI W,DONG B,PENG B,et al.Glove single-port laparoscopy-assisted transanal total mesorectal excision for low rectal cancer:a preliminary report[J].World J Surg Oncol,2019,17(1):202. LI W,DONG B,PENG B,et al.Glove single-port laparoscopy-assisted transanal total mesorectal excision for low rectal cancer:a preliminary report[J].World J Surg Oncol,2019,17(1):202.
17、 LIU H,ZENG Z,ZHANG H,et al.Morbidity,mortality,and pathologic outcomes of transanal versus laparoscopic total mesorectal excision for rectal cancer short-term outcomes from a multicenter randomized controlled trial[J].Ann Surg,2023,277(1):1-6. LIU H,ZENG Z,ZHANG H,et al.Morbidity,mortality,and pathologic outcomes of transanal versus laparoscopic total mesorectal excision for rectal cancer short-term outcomes from a multicenter randomized controlled trial[J].Ann Surg,2023,277(1):1-6.
18、 HE Z,PENG B,CHEN W,et al.Clinical efficacy of intersphincteric resection for low rectal cancer compared with abdominoperineal resection:A single-center retrospective study[J].Am Surg,2023,89(4):1009-1017. HE Z,PENG B,CHEN W,et al.Clinical efficacy of intersphincteric resection for low rectal cancer compared with abdominoperineal resection:A single-center retrospective study[J].Am Surg,2023,89(4):1009-1017.
19、 PENG B,LU J,WU Z,et al.Intersphincteric resection versus abdominoperineal resection for low rectal cancer:A meta-analysis[J].Surg Innov,2020,27(4):392-401. PENG B,LU J,WU Z,et al.Intersphincteric resection versus abdominoperineal resection for low rectal cancer:A meta-analysis[J].Surg Innov,2020,27(4):392-401.
20、 MIRSHAHVALAD S A,HINZPETER R,KOHAN A,et al.Diagnostic performance of[18F]-FDG PET/MR in evaluating colorectal cancer:A systematic review and meta-analysis[J].Eur J Nucl Med Mol Imaging,2022,49(12):4205-4217. MIRSHAHVALAD S A,HINZPETER R,KOHAN A,et al.Diagnostic performance of[18F]-FDG PET/MR in evaluating colorectal cancer:A systematic review and meta-analysis[J].Eur J Nucl Med Mol Imaging,2022,49(12):4205-4217.
21、 LIU Y,WAN L,PENG W,et al.A magnetic resonance imaging(MRI)-based nomogram for predicting lymph node metastasis in rectal cancer:A node-for-node comparative study of MRI and histopathology[J].Quant Imaging Med Surg,2021,11(6):2586-2597. LIU Y,WAN L,PENG W,et al.A magnetic resonance imaging(MRI)-based nomogram for predicting lymph node metastasis in rectal cancer:A node-for-node comparative study of MRI and histopathology[J].Quant Imaging Med Surg,2021,11(6):2586-2597.
22、 JIA H,JIANG X,ZHANG K,et al.A nomogram of combining IVIM-DWI and MRI radiomics from the primary lesion of rectal adenocarcinoma to assess nonenlarged lymph node metastasis preoperatively[J].J Magn Reson Imaging,2022,56(3):658-667. JIA H,JIANG X,ZHANG K,et al.A nomogram of combining IVIM-DWI and MRI radiomics from the primary lesion of rectal adenocarcinoma to assess nonenlarged lymph node metastasis preoperatively[J].J Magn Reson Imaging,2022,56(3):658-667.
23、 杨艳红,严超贵,何洁珺,等.二种直肠充盈方法对直肠癌高分辨率MRI检查图像质量的探讨[J].中华消化病与影像杂志(电子版),2017,7(6):257-260. 杨艳红,严超贵,何洁珺,等.二种直肠充盈方法对直肠癌高分辨率MRI检查图像质量的探讨[J].中华消化病与影像杂志(电子版),2017,7(6):257-260.
24、 CHEN L D,LIANG J Y,WU H,et al.Multiparametric radiomics improve prediction of lymph node metastasis of rectal cancer compared with conventional radiomics[J].Life Sci,2018(208):55-63. CHEN L D,LIANG J Y,WU H,et al.Multiparametric radiomics improve prediction of lymph node metastasis of rectal cancer compared with conventional radiomics[J].Life Sci,2018(208):55-63.
25、 HUANG Y,LIANG C,HE L,et al.Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer[J].J Clin Oncol,2016,34(18):2157-2164. HUANG Y,LIANG C,HE L,et al.Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer[J].J Clin Oncol,2016,34(18):2157-2164.
26、 NERAD E,LAHAYE M J,MAAS M,et al.Diagnostic accuracy of CT for local staging of colon cancer:A systematic review and meta-analysis[J].Am J Roentgenol Am J Roentgenol,2016,207(5):984-995. NERAD E,LAHAYE M J,MAAS M,et al.Diagnostic accuracy of CT for local staging of colon cancer:A systematic review and meta-analysis[J].Am J Roentgenol Am J Roentgenol,2016,207(5):984-995.
27、 SCHOEN R E,PINSKY P F,WEISSFELD J L,et al.Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy[J].N Engl J Med,2012,366(25):2345-2357. SCHOEN R E,PINSKY P F,WEISSFELD J L,et al.Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy[J].N Engl J Med,2012,366(25):2345-2357.
28、 LADABAUM U,DOMINITZ J A,KAHI C,et al.Strategies for colorectal cancer screening[J].Gastroenterology,2020,158(2):418-432. LADABAUM U,DOMINITZ J A,KAHI C,et al.Strategies for colorectal cancer screening[J].Gastroenterology,2020,158(2):418-432.
29、 BAXTER N N,WARREN J L,BARRETT M J,et al.Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty[J].J Clin Oncol,2012,30(21):2664-2669. BAXTER N N,WARREN J L,BARRETT M J,et al.Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty[J].J Clin Oncol,2012,30(21):2664-2669.
30、 ZAPKA J,KLABUNDE C N,TAPLIN S,et al.Screening colonoscopy in the US:Attitudes and practices of primary care physicians[J].J Gen Intern Med,2012,27(9):1150-1158. ZAPKA J,KLABUNDE C N,TAPLIN S,et al.Screening colonoscopy in the US:Attitudes and practices of primary care physicians[J].J Gen Intern Med,2012,27(9):1150-1158.
31、 MARCUELLO M,DURAN-SANCHON S,MORENO L,et al.Analysis of A 6-mirna signature in serum from colorectal cancer screening participants as non-invasive biomarkers for advanced adenoma and colorectal cancer detection[J].Cancers,2019,11(10):1542. MARCUELLO M,DURAN-SANCHON S,MORENO L,et al.Analysis of A 6-mirna signature in serum from colorectal cancer screening participants as non-invasive biomarkers for advanced adenoma and colorectal cancer detection[J].Cancers,2019,11(10):1542.
32、 RACILA E,EUHUS D,WEISS A J,et al.Detection and characterization of carcinoma cells in the blood[J].Proc Natl Acad Sci USA,1998,95(8):4589-4594. RACILA E,EUHUS D,WEISS A J,et al.Detection and characterization of carcinoma cells in the blood[J].Proc Natl Acad Sci USA,1998,95(8):4589-4594.
33、 HENRIKSEN T V,TARAZONA N,FRYDENDAHL A,et al.Circulating tumor DNA in stage III colorectal cancer,beyond minimal residual disease detection,toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences[J].Clin Cancer Res,2022,28(3):507-517. HENRIKSEN T V,TARAZONA N,FRYDENDAHL A,et al.Circulating tumor DNA in stage III colorectal cancer,beyond minimal residual disease detection,toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences[J].Clin Cancer Res,2022,28(3):507-517.
34、 JUNG G,HERNáNDEZ-ILLáN E,MOREIRA L,et al.Epigenetics of colorectal cancer:Biomarker and therapeutic potential[J].Nat Rev Gastroenterol Hepatol,2020,17(2):111-130. JUNG G,HERNáNDEZ-ILLáN E,MOREIRA L,et al.Epigenetics of colorectal cancer:Biomarker and therapeutic potential[J].Nat Rev Gastroenterol Hepatol,2020,17(2):111-130.
35、 KALIMUTHO M,DEL VECCHIO BLANCO G,DI CECILIA S,et al.Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer[J].J Gastroenterol,2011,46(12):1391-1402. KALIMUTHO M,DEL VECCHIO BLANCO G,DI CECILIA S,et al.Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer[J].J Gastroenterol,2011,46(12):1391-1402.
36、 BETTEGOWDA C,SAUSEN M,LEARY R J,et al.Detection of circulating tumor DNA in early- and late-stage human malignancies[J].Sci Transl Med,2014,6(224):224ra24. BETTEGOWDA C,SAUSEN M,LEARY R J,et al.Detection of circulating tumor DNA in early- and late-stage human malignancies[J].Sci Transl Med,2014,6(224):224ra24.
37、 LUO H,ZHAO Q,WEI W,et al.Circulating tumor DNA methylation profiles enable early diagnosis,prognosis prediction,and screening for colorectal cancer[J].Sci Transl Med,2020,12(524):eaax7533. LUO H,ZHAO Q,WEI W,et al.Circulating tumor DNA methylation profiles enable early diagnosis,prognosis prediction,and screening for colorectal cancer[J].Sci Transl Med,2020,12(524):eaax7533.
38、 VANHAESEBROECK B,BILANGES B,MADSEN R R,et al.Perspective:Potential impact and therapeutic implications of oncogenic PI3K activation on chromosomal instability[J].Biomolecules,2019,9(8):331. VANHAESEBROECK B,BILANGES B,MADSEN R R,et al.Perspective:Potential impact and therapeutic implications of oncogenic PI3K activation on chromosomal instability[J].Biomolecules,2019,9(8):331.
39、 MARCUELLO M,VYMETALKOVA V,NEVES RPL,et al.Circulating biomarkers for early detection and clinical management of colorectal cancer[J].Mol Aspects Med,2019(69):107-122. MARCUELLO M,VYMETALKOVA V,NEVES RPL,et al.Circulating biomarkers for early detection and clinical management of colorectal cancer[J].Mol Aspects Med,2019(69):107-122.
40、 陈万青,李霓,兰平,等.中国结直肠癌筛查与早诊早治指南(2020,北京)[J].中国肿瘤,2021,30(1):1-28. 陈万青,李霓,兰平,等.中国结直肠癌筛查与早诊早治指南(2020,北京)[J].中国肿瘤,2021,30(1):1-28.
41、 国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化内镜学分会,等.中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J].中华消化内镜杂志,2019,36(10):709-719. 国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化内镜学分会,等.中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J].中华消化内镜杂志,2019,36(10):709-719.
42、 LEE J K,LILES E G,BENT S,et al.Accuracy of fecal immunochemical tests for colorectal cancer:Systematic review and meta-analysis[J].Ann Intern Med,2014,160(3):171. LEE J K,LILES E G,BENT S,et al.Accuracy of fecal immunochemical tests for colorectal cancer:Systematic review and meta-analysis[J].Ann Intern Med,2014,160(3):171.
43、 ALLISON J E,TEKAWA I S,RANSOM L J,et al.A comparison of fecal occult-blood tests for colorectal-cancer screening[J].N Engl J Med,1996,334(3):155-160. ALLISON J E,TEKAWA I S,RANSOM L J,et al.A comparison of fecal occult-blood tests for colorectal-cancer screening[J].N Engl J Med,1996,334(3):155-160.
44、 CHIU H M,CHEN S L,YEN A M,et al.Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program[J].Cancer,2015,121(18):3221-3229. CHIU H M,CHEN S L,YEN A M,et al.Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program[J].Cancer,2015,121(18):3221-3229.
45、 SHAUKAT A,LEVIN T R.Current and future colorectal cancer screening strategies[J].Nat Rev Gastroenterol Hepatol,2022,19(8):521-531. SHAUKAT A,LEVIN T R.Current and future colorectal cancer screening strategies[J].Nat Rev Gastroenterol Hepatol,2022,19(8):521-531.
46、 FENG Z,CAO J,NIE Y,et al.Analysis of population-based colorectal cancer screening in Guangzhou,2011-2015[J].Cancer Med,2019,8(5):2496-2502. FENG Z,CAO J,NIE Y,et al.Analysis of population-based colorectal cancer screening in Guangzhou,2011-2015[J].Cancer Med,2019,8(5):2496-2502.
47、 中华人民共和国国家卫生健康委员会.中国结直肠癌诊疗规范(2020年版)[J].中华外科杂志,2020,58(8):561-585. 中华人民共和国国家卫生健康委员会.中国结直肠癌诊疗规范(2020年版)[J].中华外科杂志,2020,58(8):561-585.
48、 KANTH P,INADOMI J M.Screening and prevention of colorectal cancer[J].BMJ, 2021(374):n1855. KANTH P,INADOMI J M.Screening and prevention of colorectal cancer[J].BMJ, 2021(374):n1855.
1、张燃.探讨直肠癌新辅助治疗后肿瘤退缩分级的影响因素及其与预后的相关性[D].大连医科大学,2024.DOI:10.26994/d.cnki.gdlyu.2024.001223. 张燃.探讨直肠癌新辅助治疗后肿瘤退缩分级的影响因素及其与预后的相关性[D].大连医科大学,2024.DOI:10.26994/d.cnki.gdlyu.2024.001223.
2、杨柳.SLX4IP在结直肠癌中的表达及其临床意义[D].大连医科大学,2024.DOI:10.26994/d.cnki.gdlyu.2024.000286. 杨柳.SLX4IP在结直肠癌中的表达及其临床意义[D].大连医科大学,2024.DOI:10.26994/d.cnki.gdlyu.2024.000286.
3、石玉琢.益气通络解毒方联合化疗及靶向治疗晚期结直肠癌的临床研究[D].安徽中医药大学,2024.DOI:10.26922/d.cnki.ganzc.2024.000482. 石玉琢.益气通络解毒方联合化疗及靶向治疗晚期结直肠癌的临床研究[D].安徽中医药大学,2024.DOI:10.26922/d.cnki.ganzc.2024.000482.
4、冯妍琪.基于真实世界研究霍介格教授中医药治疗对结直肠癌患者生存质量的影响[D].南京中医药大学,2024.DOI:10.27253/d.cnki.gnjzu.2024.000355. 冯妍琪.基于真实世界研究霍介格教授中医药治疗对结直肠癌患者生存质量的影响[D].南京中医药大学,2024.DOI:10.27253/d.cnki.gnjzu.2024.000355.
5、李继晟.蚕蛹油抑制结直肠癌病理进展的作用及机制研究[D].西南大学,2024.DOI:10.27684/d.cnki.gxndx.2024.003719. 李继晟.蚕蛹油抑制结直肠癌病理进展的作用及机制研究[D].西南大学,2024.DOI:10.27684/d.cnki.gxndx.2024.003719.
6、梁宇婷.LncRNAH19介导DNA损伤修复在直肠癌放疗敏感性中的作用[D].内蒙古医科大学,2024.DOI:10.27231/d.cnki.gnmyc.2024.000832. 梁宇婷.LncRNAH19介导DNA损伤修复在直肠癌放疗敏感性中的作用[D].内蒙古医科大学,2024.DOI:10.27231/d.cnki.gnmyc.2024.000832.
7、张越.联合生信分析探讨YAP差异性表达对结直肠癌生存预后的影响[D].桂林医学院,2024.DOI:10.27806/d.cnki.gglyx.2024.000194. 张越.联合生信分析探讨YAP差异性表达对结直肠癌生存预后的影响[D].桂林医学院,2024.DOI:10.27806/d.cnki.gglyx.2024.000194.
8、李硕.粘蛋白MUC5AC在结肠癌组织中的表达及意义[D].桂林医学院,2024.DOI:10.27806/d.cnki.gglyx.2024.000110. 李硕.粘蛋白MUC5AC在结肠癌组织中的表达及意义[D].桂林医学院,2024.DOI:10.27806/d.cnki.gglyx.2024.000110.
9、彭夕珂.健脾清肠方联合化疗靶向治疗脾肾阳虚型转移性结直肠癌的临床研究[D].重庆医科大学,2024.DOI:10.27674/d.cnki.gcyku.2024.001422. 彭夕珂.健脾清肠方联合化疗靶向治疗脾肾阳虚型转移性结直肠癌的临床研究[D].重庆医科大学,2024.DOI:10.27674/d.cnki.gcyku.2024.001422.
10、廖欣.上臂围和小腿围对结直肠癌患者肌肉减少症和恶液质的预测价值研究[D].西南医科大学,2024.DOI:10.27215/d.cnki.glzyu.2024.000101. 廖欣.上臂围和小腿围对结直肠癌患者肌肉减少症和恶液质的预测价值研究[D].西南医科大学,2024.DOI:10.27215/d.cnki.glzyu.2024.000101.
11、段浩楠.基于多尺度特征融合的特定医学影像分割方法研究及应用[D].北京化工大学,2024.DOI:10.26939/d.cnki.gbhgu.2024.001900. 段浩楠.基于多尺度特征融合的特定医学影像分割方法研究及应用[D].北京化工大学,2024.DOI:10.26939/d.cnki.gbhgu.2024.001900.
12、陆玥瑶.NKD1在结肠癌细胞迁移中的作用及其临床意义[D].南京医科大学,2024.DOI:10.27249/d.cnki.gnjyu.2024.001364. 陆玥瑶.NKD1在结肠癌细胞迁移中的作用及其临床意义[D].南京医科大学,2024.DOI:10.27249/d.cnki.gnjyu.2024.001364.
13、陈一凡.基于代谢组学探究青龙衣浓缩丸治疗结直肠癌的临床疗效研究[D].黑龙江省中医药科学院,2024.DOI:10.27126/d.cnki.ghlzy.2024.000138. 陈一凡.基于代谢组学探究青龙衣浓缩丸治疗结直肠癌的临床疗效研究[D].黑龙江省中医药科学院,2024.DOI:10.27126/d.cnki.ghlzy.2024.000138.
14、冯文斌.青龙衣多糖联合PD-1抑制剂治疗结肠癌的作用及机制研究[D].黑龙江省中医药科学院,2024.DOI:10.27126/d.cnki.ghlzy.2024.000002. 冯文斌.青龙衣多糖联合PD-1抑制剂治疗结肠癌的作用及机制研究[D].黑龙江省中医药科学院,2024.DOI:10.27126/d.cnki.ghlzy.2024.000002.
15、金聪健.大肠癌不同中医证型的舌象特征和舌苔菌群的相关性研究[D].浙江中医药大学,2024.DOI:10.27465/d.cnki.gzzyc.2024.000660. 金聪健.大肠癌不同中医证型的舌象特征和舌苔菌群的相关性研究[D].浙江中医药大学,2024.DOI:10.27465/d.cnki.gzzyc.2024.000660.
16、李俊蓉.结直肠癌中TMED4与免疫微环境的关系[D].贵州医科大学,2024.DOI:10.27045/d.cnki.ggyyc.2024.000391. 李俊蓉.结直肠癌中TMED4与免疫微环境的关系[D].贵州医科大学,2024.DOI:10.27045/d.cnki.ggyyc.2024.000391.
17、乔艳萍.循环肿瘤DNA甲基化与Ⅱ期结直肠癌术后患者预后的相关性研究[D].河南大学,2024.DOI:10.27114/d.cnki.ghnau.2024.003362. 乔艳萍.循环肿瘤DNA甲基化与Ⅱ期结直肠癌术后患者预后的相关性研究[D].河南大学,2024.DOI:10.27114/d.cnki.ghnau.2024.003362.
18、应浃飞.miR-379-5p和miR-7-5p对结直肠癌细胞生物学行为和药物敏感性的影响及其机制探讨[D].延安大学,2024.DOI:10.27438/d.cnki.gyadu.2024.000902. 应浃飞.miR-379-5p和miR-7-5p对结直肠癌细胞生物学行为和药物敏感性的影响及其机制探讨[D].延安大学,2024.DOI:10.27438/d.cnki.gyadu.2024.000902.
19、黄佳茹.NUP107在结直肠癌中的表达及生物学作用的研究[D].吉林大学,2024.DOI:10.27162/d.cnki.gjlin.2024.004579. 黄佳茹.NUP107在结直肠癌中的表达及生物学作用的研究[D].吉林大学,2024.DOI:10.27162/d.cnki.gjlin.2024.004579.
20、常肖璐.CX-5461通过NRF2信号通路诱导结直肠癌细胞铁死亡的分子机制研究[D].延边大学,2024.DOI:10.27439/d.cnki.gybdu.2024.000497. 常肖璐.CX-5461通过NRF2信号通路诱导结直肠癌细胞铁死亡的分子机制研究[D].延边大学,2024.DOI:10.27439/d.cnki.gybdu.2024.000497.
21、袁经芳.结直肠癌HMGB2蛋白定位及与P53表型关系的临床病理研究[D].赣南医科大学,2024.DOI:10.27959/d.cnki.ggnyx.2024.000245. 袁经芳.结直肠癌HMGB2蛋白定位及与P53表型关系的临床病理研究[D].赣南医科大学,2024.DOI:10.27959/d.cnki.ggnyx.2024.000245.
22、唐义猛.基于肠道菌群和代谢组学探究黄芪的抗结直肠癌的作用机制[D].成都医学院,2025.DOI:10.27843/d.cnki.gcdyy.2025.000248. 唐义猛.基于肠道菌群和代谢组学探究黄芪的抗结直肠癌的作用机制[D].成都医学院,2025.DOI:10.27843/d.cnki.gcdyy.2025.000248.
23、陈梦洁.基于数据挖掘分析张晓春教授辨治结直肠癌术后用药规律及经验探析[D].扬州大学,2025.DOI:10.27441/d.cnki.gyzdu.2025.002914. 陈梦洁.基于数据挖掘分析张晓春教授辨治结直肠癌术后用药规律及经验探析[D].扬州大学,2025.DOI:10.27441/d.cnki.gyzdu.2025.002914.
24、廖巍.CD73和PIKE在结直肠癌中的表达及与临床病理特征的关系[D].右江民族医学院,2025.DOI:10.27908/d.cnki.gymzy.2025.000479. 廖巍.CD73和PIKE在结直肠癌中的表达及与临床病理特征的关系[D].右江民族医学院,2025.DOI:10.27908/d.cnki.gymzy.2025.000479.
25、朱梦颖.黄芩汤对小鼠结直肠癌的发生及其肠道菌群的作用研究[D].辽宁中医药大学,2025.DOI:10.27213/d.cnki.glnzc.2025.000201. 朱梦颖.黄芩汤对小鼠结直肠癌的发生及其肠道菌群的作用研究[D].辽宁中医药大学,2025.DOI:10.27213/d.cnki.glnzc.2025.000201.
26、郭振,王子晨,张康洋,等.中低位直肠癌根治术后实现教科书式结局的影响因素分析及预测模型的建立[J].胃肠病学和肝病学杂志,2024,33(08):999-1004. 郭振,王子晨,张康洋,等.中低位直肠癌根治术后实现教科书式结局的影响因素分析及预测模型的建立[J].胃肠病学和肝病学杂志,2024,33(08):999-1004.
27、汪家航,林明强.血清VEGF、TPS及CEA在结直肠癌诊断中的研究进展[J].中外医学研究,2024,22(24):179-181.DOI:10.14033/j.cnki.cfmr.2024.24.045. 汪家航,林明强.血清VEGF、TPS及CEA在结直肠癌诊断中的研究进展[J].中外医学研究,2024,22(24):179-181.DOI:10.14033/j.cnki.cfmr.2024.24.045.
28、张朓,郝玉通,文海燕,等.粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究[J].重庆医科大学学报,2025,50(07):983-987.DOI:10.13406/j.cnki.cyxb.003786. 张朓,郝玉通,文海燕,等.粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究[J].重庆医科大学学报,2025,50(07):983-987.DOI:10.13406/j.cnki.cyxb.003786.
29、万璐颖,李静宜,谢贤和.基于生物信息学分析TRIB2与结肠癌预后和免疫浸润相关性[J].广州医药,2025,56(06):766-774.DOI:10.20223/j.cnki.1000-8535.2025.06.006. 万璐颖,李静宜,谢贤和.基于生物信息学分析TRIB2与结肠癌预后和免疫浸润相关性[J].广州医药,2025,56(06):766-774.DOI:10.20223/j.cnki.1000-8535.2025.06.006.
30、张瑞航,单增卓嘎,米玛卓嘎,等.芍药汤通过促进活性氧依赖性自噬以抑制结直肠癌发展和转移[J].中华中医药学刊,2025,43(11):172-176+294.DOI:10.13193/j.issn.1673-7717.2025.11.034. 张瑞航,单增卓嘎,米玛卓嘎,等.芍药汤通过促进活性氧依赖性自噬以抑制结直肠癌发展和转移[J].中华中医药学刊,2025,43(11):172-176+294.DOI:10.13193/j.issn.1673-7717.2025.11.034.
下一篇
作者登录
作者注册
审稿登录
编辑登录
最新资讯

“胶质瘤精准诊疗”专题征稿启事

发布于: 2026-05-29

“精神心理与脑科学：前沿与实践”专题征稿启事

发布于: 2026-05-29

“人工智能与医学融合”专题征稿启事

发布于: 2025-02-19

征稿 |《广州医药》—“医院管理”专栏征稿

发布于: 2025-01-21
学术活动

会议通知|人工智能赋能学科高质量发展专题讲座

发布于: 2025-02-19

广州市第一人民医院烧伤整形美容与创面修复科举办首期EWMA创面管理与修复培训班

发布于: 2026-05-29

提质增效，创新作为，不断提升麻醉服务能力2024工作总结与2025工作计划

发布于: 2025-02-19

2026年广州市医学会血液学分会学术年会暨再生障碍性贫血研讨会圆满落幕

发布于: 2026-06-01
出版者信息






《广州医药》公众号
目录
友情链接
关注微信公众号
首页   | 关于我们   | 联系我们  粤ICP备17084739号-3
关注微信公众号
粤ICP备17084739号-3